Market Place
Sourcing Support
Neurocrine`s drug cuts schizophrenia symptoms in mid-stage study
29 Aug 2024 //
REUTERS
Karuna`s captains set sail in new neuropsychiatric biotech
09 Apr 2024 //
FIERCE BIOTECH
BMS Completes Acquisition of PureTech`s Founded Entity Karuna for $14 Billion
18 Mar 2024 //
BUSINESSWIRE
Karuna Therapeutics set to merge with Bristol-Myers Squibb
13 Mar 2024 //
PRESS RELEASE
Karuna ‘vigorously’ denies wrongdoing in shareholder lawsuit
01 Mar 2024 //
FIERCE BIOTECH
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
BUSINESSWIRE
Karuna shareholder sues biotech over BMS merger
15 Feb 2024 //
FIERCE BIOTECH
Third Rock adds 3 new venture partners, including Karuna’s Paul
25 Jan 2024 //
FIERCE BIOTECH
Another company bid against BMS` $14B offer for Karuna
22 Jan 2024 //
FIERCE BIOTECH
Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion
24 Dec 2023 //
INDIAN PHARMA POST
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln
23 Dec 2023 //
REUTERS
Karuna Announces Lancet Publication of Data from Phase 3 Trial Evaluating KarXT
14 Dec 2023 //
BUSINESSWIRE
Karuna Therapeutics Announces FDA Accepts NDA for KarXT
29 Nov 2023 //
BUSINESSWIRE
Karuna`s schizophrenia drug clears blood pressure test
17 Nov 2023 //
FIERCE BIOTECH
Karuna Announces Positive Results from Phase 1b Trial of KarXT
16 Nov 2023 //
BUSINESSWIRE
Karuna Therapeutics Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Karuna Therapeutics to Present at Upcoming Investor Conferences
01 Nov 2023 //
BUSINESSWIRE
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT
01 Nov 2023 //
BUSINESSWIRE
Exclusive: Trailing Karuna, MapLight Therapeutics aims to improve schizophrenia
30 Oct 2023 //
ENDPTS
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results
19 Oct 2023 //
BUSINESSWIRE
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT
04 Oct 2023 //
BUSINESSWIRE
Karuna`s journey from `serendipitous clinical finding` to FDA
04 Oct 2023 //
FIERCE BIOTECH
Karuna Therapeutics Submits New Drug Application to FDA for KarXT
28 Sep 2023 //
BUSINESSWIRE
Karuna’s new schizophrenia drug reaches FDA’s desk
28 Sep 2023 //
FIERCE BIOTECH
LB Pharmaceuticals raising $75M for schizophrenia drug
22 Sep 2023 //
ENDPTS
Karuna Therapeutics Announces Leadership Appointments
03 Aug 2023 //
BUSINESSWIRE
Karuna Therapeutics Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results
20 Jul 2023 //
BUSINESSWIRE
Karuna to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
30 May 2023 //
BUSINESSWIRE
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT
22 May 2023 //
BUSINESSWIRE
Karuna Therapeutics Reports 1Q 2023 FYR and Provides General Business Updates
04 May 2023 //
BUSINESSWIRE
Karuna Therapeutics to Announce First Quarter 2023 Financial Results
20 Apr 2023 //
BUSINESSWIRE
Karuna Announces Closing of Offering & Exercise of Option to Purchase Shares
24 Mar 2023 //
BUSINESSWIRE
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
23 Mar 2023 //
BUSINESSWIRE
Royalty swoops in with $100M upfront for slice of Karuna`s KarXT
23 Mar 2023 //
FIERCE BIOTECH
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
21 Mar 2023 //
BUSINESSWIRE
Karuna’s schizophrenia drug succeeds in a second late-stage trial
21 Mar 2023 //
BIOPHARMADIVE
Karuna Announces Positive Results from Phase 3 Trial of KarXT in Schizophrenia
20 Mar 2023 //
PRESS RELEASE
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
20 Mar 2023 //
BUSINESSWIRE
Karuna Reports Fourth Quarter and Full Year 2022 Financial Result
23 Feb 2023 //
BUSINESSWIRE
Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
09 Feb 2023 //
BUSINESSWIRE
Karuna plunders Goldfinch`s nest to pad neuroscience pipeline
03 Feb 2023 //
FIERCE BIOTECH
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
31 Jan 2023 //
BUSINESSWIRE
Karuna CEO says biotech can launch drugs too, amid deal rumors
10 Jan 2023 //
FIERCEBIOTECH
JPM Day 2: VCs still have cash for biotech, Karuna`s solo plans
10 Jan 2023 //
FIERCEBIOTECH
Karuna executive departs in lead up to pivotal drug launch
06 Jan 2023 //
FIERCE BIOTECH
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
BUSINESSWIRE
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
06 Dec 2022 //
BUSINESSWIRE
Karuna Therapeutics Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
BUSINESSWIRE
Karuna Therapeutics to Present at the Jefferies 2022 London Conference
01 Nov 2022 //
BUSINESSWIRE
Is Karuna Therapeutics (KRTX) Stock Bullish Now?
01 Nov 2022 //
FIANANCE YAHOO
PsychoGenics Announces Extension of Collaboration with Karuna Therapeutics
11 Oct 2022 //
BUSINESSWIRE
PsychoGenics Announces Extension of Drug Discovery Collaboration with Karuna
11 Oct 2022 //
BUSINESSWIRE
Karuna to Present Data from the PIII EMERGENT-2 Trial of KarXT in Schizophrenia
06 Oct 2022 //
BUSINESSWIRE
Karuna Therapeutics to Present at Upcoming Investor Conferences
01 Sep 2022 //
BUSINESSWIRE
Segal Trials Participation in Study Shows Results From Phase 3 EMERGENT-2 KarXT
23 Aug 2022 //
BUSINESSWIRE
Biotech`s `sugar high` led to a correction, but winter doldrums could make way
23 Aug 2022 //
ENDPTS
Karuna Therapeutics Announces Closing of Public Offering & Full Exercise Option
12 Aug 2022 //
BUSINESSWIRE
Karuna announces positive results from Phase III trial into schizophrenia
10 Aug 2022 //
PHARMA FILE
Zai Partner Karuna Announces Results from PIII EMERGENT-2 Trial of KarXT
08 Aug 2022 //
PRESS RELEASE
